Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Monday, Zacks.com reports. The firm currently has a $0.50 target price on the specialty pharmaceutical company’s stock. Zacks Investment Research‘s price target points to a potential downside of 4.69% from the stock’s current price.
According to Zacks, “Ampio Pharmaceuticals, Inc. develops proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. Principal products offered by the Company include Optina, an oral drug for the treatment of diabetic retinopathy and macular edema; and Vasaloc, an oral drug for the treatment of diabetic nephropathy. Ampio Pharmaceuticals, Inc. is based in Greenwood Village, Colorado. “
AMPE opened at $0.52 on Monday. Ampio Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $1.31.
Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) last posted its quarterly earnings data on Wednesday, May 6th. The specialty pharmaceutical company reported ($0.04) EPS for the quarter, meeting the consensus estimate of ($0.04).
A number of large investors have recently modified their holdings of AMPE. CVA Family Office LLC bought a new stake in Ampio Pharmaceuticals during the 4th quarter worth about $684,000. Western Wealth Management LLC bought a new stake in Ampio Pharmaceuticals during the 1st quarter worth about $316,000. HNP Capital LLC bought a new stake in Ampio Pharmaceuticals during the 1st quarter worth about $200,000. Advisor Group Holdings Inc. bought a new stake in Ampio Pharmaceuticals during the 1st quarter worth about $42,000. Finally, Noven Financial Group Inc. lifted its position in Ampio Pharmaceuticals by 64.4% during the 1st quarter. Noven Financial Group Inc. now owns 202,459 shares of the specialty pharmaceutical company’s stock worth $84,000 after buying an additional 79,287 shares in the last quarter.
Ampio Pharmaceuticals Company Profile
Ampio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee.
See Also: Understanding the two types of arbitrage
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.